Molecularly targeted therapies for human hepatocellular carcinoma: Should we start from b-catenin inhibition?

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 257-259

  Calvisi, Diego F ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN, MOUSE; DNA; LOCKED NUCLEIC ACID; OLIGONUCLEOTIDE;

CELL ADHESION; HUMAN; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; CARCINOGENESIS; EXPERIMENTAL LIVER NEOPLASM; GENETICS; MALE; METABOLISM; MUTATION;

ANIMALS; BETA CATENIN; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; DNA, NEOPLASM; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MUTATION; OLIGONUCLEOTIDES;

EID: 84922239094     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.11.021     Document Type: Review

References (20)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
3. European Association for the Study of the Liver. EOfRaToC. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
4. Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis 2011; 15: 423-441.
5. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the b-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998; 85: 8847-8851.
6. Nejak-Bowen KN, Monga SPS. Beta-catenin signaling, liver regeneration and hepatocellular cancer: Sorting the good from the bad. Semin Cancer Biol 2011; 21: 44-58.
7. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999; 9: 15-21.
8. Gumbiner BM. Signal transduction by b-catenin. Curr Opin Cell Biol 1995; 7: 634-640.
9. Clevers H, Van de Wetering M. TCF/LEF factors earns their wings. Trends Genet 1997; 13: 485-489.
10. Cadoret A, Ovejero C, Saadi-Kheddouci S, Souil E, Fabre M, Romagnolo B, et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 2001; 61: 3245-3249.
11. Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, Taketo MM. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 2004; 64: 48-54.
12. Colnot S,Decaens T, Niwa-KawakitaM,Godard C,HamardG,KahnA, et al. Livertargeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A 2004; 101: 17216-17221.
13. Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol 2014; 184: 912-923.
14. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120: 1763-1773.
15. Delgado E, Okabe H, Preziosi M, Russell JO, Feliciano Alvarado T, Oertel M, et al. Complete response of CTNNB1-mutated tumors to beta-catenin suppression by locked nucleic antisense in mouse hepatocarcinogenesis model. J Hepatol 2015; 62: 380-387.
16. Loeppen S, Schneider D, Gaunitz F, Gebhardt R, Kurek R, Buchmann A, et al. Overexpression of glutamine synthetase is associated with beta-cateninmutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res 2002; 62: 5685-5688.
17. Okabe H, Delgado E, Lee JM, Yang J, Kinoshita H, Hayashi H, et al. Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma. PLoS One 2014; 9: E98817.
18. Horwitz E, Stein I, Andreozzi M, Nemeth J, Shoham A, Pappo O, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 2014; 4: 730-743.
19. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63.
20. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57-67.